Company intelligence / Profile preview

Ammonett Pharma LLC

Midlothian, Virginia, United States

Ownership: Private
Development stage: Other

Overview

Developed LUM-201 (previously MK-0677), an oral small molecule growth hormone secretagogue; licensed to Lumos Pharma in 2018; received Orphan Drug Designation in US and positive opinion in EU for PGHD

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Lumos Pharma (licensee for LUM-201)

Beyond the preview

Go deeper on Ammonett Pharma LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ammonett Pharma LLC.

Explore the full profile